Automatic bone marrow segmentation for precise [177Lu]Lu‐PSMA‐617 dosimetry
Sign Up to like & getrecommendations! Published in 2025 at "Medical Physics"
DOI: 10.1002/mp.17684
Abstract: Bone marrow (BM) is the dominant dose‐limiting organ in [177Lu]Lu‐PSMA‐617 therapy for patients with metastasized castration resistant prostate cancer, where BM dosimetry is challenging due to segmentation. read more here.
Keywords: bone marrow; 177lu psma; psma 617;
Transforming [177Lu]Lu‐PSMA‐617 treatment planning: Machine learning‐based radiodosiomics and swin UNETR using pretherapy PSMA positron emission tomography/computed tomography (PET/CT)
Sign Up to like & getrecommendations! Published in 2025 at "Medical Physics"
DOI: 10.1002/mp.70030
Abstract: Personalized pretreatment dosimetry planning is crucial for optimizing [177Lu]Lu–prostate‐specific membrane antigen‐617 (Lu‐PSMA) radioligand therapy (RLT) in patients with metastatic castration‐resistant prostate cancer (mCRPC). read more here.
Keywords: psma 617; 617 treatment; transforming 177lu; psma ... See more keywords
The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer
Sign Up to like & getrecommendations! Published in 2017 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-017-3681-9
Abstract: Background[177Lu]Lu-PSMA-617 is a well-tolerated therapy for the treatment of metastatic prostate cancer. However, because of the mainly renal excretion of the tracer, the kidneys are one of the most limiting organs. The purpose of this… read more here.
Keywords: psma 617; 177lu psma; metastatic prostate; prostate cancer ... See more keywords
177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2017 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-017-3751-z
Abstract: PurposeRadioligand therapies targeting prostate-specific membrane antigen (PSMA) have been established for the treatment of metastasized castration-resistant prostate cancer (mCRPC) in the last decade and show promising response rates and a favourable toxicity profile. The aim… read more here.
Keywords: prostate; psma 617; 177lu psma; prostate cancer ... See more keywords
DNA damage in blood leucocytes of prostate cancer patients during therapy with 177Lu-PSMA
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-019-04317-4
Abstract: PurposeThe aim of this study was to investigate the time- and dose-dependency of DNA double-strand break (DSB) induction and repair in peripheral blood leucocytes of prostate cancer patients during therapy with 177Lu-PSMA.MethodsBlood samples from 16… read more here.
Keywords: 177lu psma; time; prostate cancer; blood ... See more keywords
225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-019-04612-0
Abstract: Up to 30% of patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) never respond or develop resistance to 177Lu-labeled PSMA-targeted radioligand monotherapy. Single-agent PSMA-targeted radioligand therapy (PRLT) with the alpha-emitter 225Ac showed… read more here.
Keywords: psma 617; 177lu psma; 225ac psma; tandem therapy ... See more keywords
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
Sign Up to like & getrecommendations! Published in 2020 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-020-05057-6
Abstract: Various radiolabeled prostate-specific membrane antigen (PSMA)–targeting tracers are clinically applied for prostate cancer (PCa) imaging and targeted radionuclide therapy. The PSMA binding affinities, biodistribution, and DNA-damaging capacities of these radiotracers have not yet been compared… read more here.
Keywords: psma 617; 177lu psma; prostate cancer; evaluation ... See more keywords
Efficacy and safety of rechallenge [177Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study)
Sign Up to like & getrecommendations! Published in 2024 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-024-06825-4
Abstract: Rechallenge of [177Lu]Lu-PSMA-617 radioligand therapy (RLT) was proposed for patients who initially responded to PSMA-RLT experiencing partial remission, but relapsed into progression after a certain period of remission. However, only limited data is available regarding… read more here.
Keywords: 617 rlt; rlt; psma 617; rechallenge ... See more keywords
Biodistribution and dosimetry of [177Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2025 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-025-07102-8
Abstract: Several prostate-specific membrane antigen (PSMA) radiopharmaceuticals have been used for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). In an attempt to improve the tumour accumulation, new PSMA ligands were developed with an albumin-binding entity… read more here.
Keywords: 177lu sibudab; prostate; tumour; psma ... See more keywords
Therapeutic evaluation of [212Pb]Pb-AB001 and [177Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer
Sign Up to like & getrecommendations! Published in 2025 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-025-07330-y
Abstract: Metastatic castration-resistant prostate cancer (mCRPC) frequently leads to bone and soft tissue metastases, leading to poor prognosis. The beta-emitting radioligand [177Lu]Lu-PSMA-617 targets the prostate-specific membrane antigen (PSMA) and may be less efficient against micrometastatic disease.… read more here.
Keywords: prostate cancer; psma 617; 212pb ab001; psma ... See more keywords
Hematological and renal toxicity in mice after three cycles of high activity [177Lu]Lu-PSMA-617 with or without human α1-microglobulin
Sign Up to like & getrecommendations! Published in 2024 at "Scientific Reports"
DOI: 10.1038/s41598-024-61370-2
Abstract: Radioligand therapy with [177Lu]Lu-PSMA-617 can be used to prolong life and reduce tumor burden in terminally ill castration resistant prostate cancer patients. Still, accumulation in healthy tissue limits the activity that can be administered. Therefore,… read more here.
Keywords: three cycles; psma 617; toxicity; high activity ... See more keywords